{"url":"https://lda.senate.gov/api/v1/filings/0ff97eed-e3c5-45f3-977a-2ef023a618b6/","filing_uuid":"0ff97eed-e3c5-45f3-977a-2ef023a618b6","filing_type":"4A","filing_type_display":"4th Quarter - Amendment","filing_year":2021,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/0ff97eed-e3c5-45f3-977a-2ef023a618b6/print/","filing_document_content_type":"text/html","income":"40000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Ruth Richards","dt_posted":"2022-02-04T09:45:59.223000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1341 G Street NW, 6th Floor","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":65191,"url":"https://lda.senate.gov/api/v1/registrants/65191/","house_registrant_id":35579,"name":"VENN STRATEGIES","description":"A political and public affairs consulting firm.","address_1":"750 9th St NW, Suite 650","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JAY ENGLESON","contact_telephone":"+1 301-509-9933","dt_updated":"2026-07-20T11:43:32.403140-04:00"},"client":{"id":208872,"url":"https://lda.senate.gov/api/v1/clients/208872/","client_id":1003845,"name":"AVANIR PHARMACEUTICALS, INC.","general_description":"Biopharmaceutical research and manufacturing.","client_government_entity":false,"client_self_select":null,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-02-19"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.","foreign_entity_issues":"Ownership","lobbyists":[{"lobbyist":{"id":25887,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"SILVERMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":64837,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SPIRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":93712,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COUCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}